Celgene International Sárl (CELG) Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients With Rare Form of Blood Disease
6/17/2013 9:33:05 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) was today notified that the European Commission (EC) has amended the marketing authorisation for REVLIMID®. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.1
Help employers find you! Check out all the jobs and post your resume.
comments powered by